Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

M&A/IPOs

 

Dutch physiotherapy group makes plans to go national

Dutch physiotherapy specialist TopzorgGroep has recently gained new investor. HBI talks to a Netherlands-based consultant about how the group could become a notable player in a largely chain-free market.

Will Bergman buy big before prospective sale?

Rumours persist that Bergman Clinic, the Dutch and Nordic ambulatory and ophthalmology clinic chain, is looking to sell and may have one large acquisition in its sights ahead of any process starting. HBI speaks briefly to two banking sources, and a Netherlands-based advisor to find out more.

Nordic Capital ‘buying SpaMedica’

European-focused PE firm Nordic Capital is reportedly buying SpaMedica, the UK's largest cataract surgery provider, in a deal that values the ophthalmic group at around £300m.

Asklepios moves on Rhoen – but is offer generous enough?

Germany's second-largest private hospital group Asklepios plans to launch a takeover of listed competitor Rhoen Klinikum in partnership with Rhoen's founder Eugene Muench. But Rhoen's shares have now risen above the offer price indicating this is far from a done deal.

Ameos acquires Swiss non-profit hospital

PE backed Swiss hospital and psychiatric group Ameos has acquired a majority stake in a not-for-profit hospital, its second facility in the country. The group, predominantly present in Germany and Austria, is taking advantage of a challenging climate in the Swiss hospital sector which is putting many small hospitals in financial trouble.

Primo Group and CareDent merge

For-profit dental groups CareDent and Primo Group have merged, creating a new number two player by revenue in Italy.

BDMS makes offer for Bumrungrad

Thailand’s largest private hospital operator Bangkok Dusit Medical Service (BDMS), the biggest shareholder in Bumrungrad Hospital (BH), has launched a tender offer for the remainder of the shares it doesn’t own.

NMC identifies $335m side deals and sacks CEO

In an announcement put out after trading, the independent review board appointed by NMC has identified side deals on procurement worth US$335m with the founders for which NMC is liable and that were made without board approval. It has also removed Mr Prasanth Manghat from his position of Director and CEO of the Company with immediate effect.

Find Us